33766 Efficacy of baricitinib in patients with various degrees of alopecia areata severity: Results from BRAVE-AA1 and BRAVE-AA2

Abstract

Baricitinib is an oral selective Janus kinase (JAK)1/JAK2 inhibitor with demonstrated efficacy in patients with alopecia areata (AA). This analysis evaluated the difference in response among subgroups of patients with various degree of severity based on the Severity of Alopecia Tool (SALT) score from phase 3 results of 2 randomized, double-blinded, placebo-controlled trials (BRAVE-AA1 (NCT03570749) and BRAVE-AA2 (NCT03899259)). Both BRAVE-AA1 (N = 654) and BRAVE-AA2 (N = 546) enrolled adult patients with ≥50% scalp hair loss.